Efficacy and Safety of 0.05% Ingenol Mebutate in the Treatment of Basal Cell Carcinoma: A Prospective Study
Overview
Overview
Journal
Skin Health Dis
Publisher
Oxford University Press
Specialty
Dermatology
Date
2023 Apr 4
PMID
37013127
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?.
de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, Granier F, Prevostel C Pharmaceuticals (Basel). 2024; 17(7).
PMID: 39065798 PMC: 11279613. DOI: 10.3390/ph17070949.
Skin cancer special issue in Skin Health and Disease.
Yelamos O, Geller S, Tokez S Skin Health Dis. 2023; 3(2):e224.
PMID: 37013119 PMC: 10066748. DOI: 10.1002/ski2.224.
References
1.
Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne S
. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010; 51(2):99-105.
DOI: 10.1111/j.1440-0960.2010.00626.x.
View
2.
Cameron M, Lee E, Hibler B, Barker C, Mori S, Cordova M
. Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2018; 80(2):303-317.
DOI: 10.1016/j.jaad.2018.03.060.
View
3.
Garcia-de-la-Fuente M, Santacana M, Verdaguer J, Vilardell F, Gari E, Casanova J
. Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma. Australas J Dermatol. 2020; 61(2):e200-e207.
DOI: 10.1111/ajd.13229.
View
4.
Thomson J, Hogan S, Leonardi-Bee J, Williams H, Bath-Hextall F
. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2020; 11:CD003412.
PMC: 8164471.
DOI: 10.1002/14651858.CD003412.pub3.
View